Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress

Xiaodong Zhang, Yan Li, Yingbo Ma, Liang Yang, Tao Wang, Xin Meng, Zhihong Zong, Xun Sun, Xiangdong Hua and Hangyu Li

Abstract

Background: Hypoxia-inducible factor 1α (HIF-1α) is essential in hepatocellular carcinoma (HCC) glycolysis and progression. Yes-associated protein (YAP) is a powerful regulator and is overexpressed in many cancers, including HCC. The regulatory mechanism of YAP and HIF-1α in HCC glycolysis is unknown.

Methods: We detected YAP expression in 54 matched HCC tissues and the adjacent noncancerous tissues. The relationship between YAP mRNA expression and that of HIF-1α was analyzed using The Cancer Genome Atlas HCC tissue data. We cultured HepG2 and Huh7 HCC cells under normoxic (20% O2) and hypoxic (1% O2) conditions, and measured the lactate and glucose levels, migration and invasive capability, and the molecular mechanism of HCC cell glycolysis and progression.

Results: In this study, we detected YAP expression in 54 matched HCC tissues and the adjacent noncancerous tissues. We observed that hypoxia-induced YAP activation is crucial for accelerating HCC cell glycolysis. Hypoxia inhibited the Hippo signaling pathway and promoted YAP nuclear localization, and decreased phosphorylated YAP expression in HCC cells. YAP knockdown inhibited HCC cell glycolysis under hypoxic. Mechanistically, hypoxic stress in the HCC cells promoted YAP binding to HIF-1α in the nucleus and sustained HIF-1α protein stability to bind to PKM2 gene and directly activates PKM2 transcription to accelerate glycolysis.

Conclusions: Our findings describe a new regulatory mechanism of hypoxia-mediated HCC metabolism, and YAP might be a promising therapeutic target in HCC.

Keywords: Yes-associated protein (YAP), Hypoxia, HIF-1α, HCC, Glycolysis

Background

One of the commonest cancers is hepatocellular carcinoma (HCC); in 2015, it was the primary cause of cancer death in men under 60 years of age [1]. Although surgical resection and other advanced treatment techniques have improved the survival of patients with HCC, their prognosis is still poor [2]. Therefore, identifying novel genes and elucidating the molecular mechanism of progression and glycolysis in HCC is important.

HCC, and other solid tumors, has the common feature of fast growth. However, the growth of HCC cells often exceeds growth of functional blood vessels, and there is frequently insufficient O2 supplement in the regions of HCC [3–6]. Therefore, tumor cells exist in a hypoxic environment, which is a fundamental solid tumor micro-environment characteristic. Such cells adapt to hypoxic stress by altering their glucose metabolism from oxidation to glycolysis, which provides sufficient energy and materials for cancer cell anabolic growth. In hypoxia, there is an essential role for hypoxia-inducible factor 1α
(HIF-1α) in promoting cell glycolysis. HIF-1α directly up-regulates the expression of the glycolytic genes, e.g., PKM2 (pyruvate kinase M2) [7], HK2 (hexokinase 2), and LDHA (lactate dehydrogenase A) [8, 9], to promote glycolysis in tumors. On the other hand, some oncogenes cooperate with HIF-1α to increase HIF-1α stabilization and transcriptional activity, subsequently promoting hypoxic tumor cell glycolysis [10, 11]. Therefore, investigating the regulatory mechanism between HIF-1α and HCC cell glycolysis under hypoxic conditions is worthwhile.

Yes-associated protein (YAP) is a transcriptional activator in the Hippo signaling, while Hippo signaling is a highly conserved tumor suppressor pathway, and it decreases YAP stability and promotes YAP cytoplasmic localization to decrease YAP activity [12]. In many human cancers, YAP is a possible oncogene; it modulates tumor size and tumorigenesis. In HCC, YAP expression is high and it acts as an independent prognostic marker [13–15]. The phosphorylation status and localization of YAP determines its activity; YAP activation via nuclear localization is the most important regulatory mechanism. YAP is highly expressed in various cancers: activated YAP promotes cancer cell proliferation, chemoresistance, and migration [16–18]. Recent studies have demonstrated a connection between glycolysis and YAP activity [19–21]. YAP up-regulates the expression of glucose transporter 3 (GLUT3) at transcriptional level to promote cell glycolysis [19]. Interestingly, YAP also suppresses gluconeogenesis by inhibiting the ability of PGC1α (PPARG coactivator 1α) to activate the transcription of its gluconeogenic targets by binding to their promoters [22]. Therefore, YAP appears to reprogram cellular metabolism. However, the potential regulatory mechanism of YAP and HIF-1α in HCC glycolysis is unknown.

In this study, we observed that hypoxia-induced YAP activation is crucial for accelerating HCC cell glycolysis. Hypoxia inhibited the Hippo signaling pathway and promoted YAP nuclear localization, and decreased phosphorylated YAP expression in HCC cells. YAP knockdown inhibited HCC cell glycolysis under hypoxia. Mechanistically, hypoxic stress in the HCC cells promoted YAP binding to HIF-1α in the nucleus and sustained HIF-1α protein stability to promote glycolysis. Collectively, our findings describe a new regulatory mechanism of hypoxia-mediated HCC metabolism, and YAP might be a promising therapeutic target in HCC.

**Methods**

**Clinical samples and cell culture**

Between July 2012 and November 2014, we obtained 54 tumor tissues and the paired adjacent noncancerous tissues from patients who had undergone surgical hepatectomy at the Liaoning Cancer Hospital and Institute (Shenyang, China) and who has been diagnosed with HCC by pathological examination. The patients had not undergone preoperative chemotherapy or radiotherapy. The China Medical University ethics committee approved this study (NO. 2014PS132K). All patients granted informed consent. The RNA sequencing (RNA-Seq) data from TCGA were obtained from Gene Expression Profiling Interactive Analysis (GEPIA) [23], which is based on the University of California Santa Cruz (UCSC) Xena project (http://xena.ucsc.edu).

The HepG2 and Huh7 human HCC cell lines were purchased from Shanghai Institute of Cell Bank (Shanghai, China). HepG2 cells were grown in Eagle’s Minimum Essential Medium and Huh7 cells were grown in Dulbecco’s Modified Eagle Medium. All medium containing 10% fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 μg/ml), 2 mM glutamine, and 10 mM HEPES buffer. Cells were cultured at 37 °C under 20% O2 (normoxia) or 1% O2 (hypoxia), balanced with N2 in a 3-gas incubator.

**RNA extraction, real-time PCR and RNA interference**

We extracted RNA with TRIzol (Invitrogen, Carlsbad, CA, USA) and performed real-time PCR as has been described previously [24]. The primers used are listed in Additional file 1: Table S1.

All HCC cell transfections were performed in 6-well plates using Invitrogen Lipofectamine 3000 (Thermo Fisher Scientific, Shanghai, China) as per instructions from the manufacturer. We harvested the cells after 48 h to perform real-time PCR or western blotting. Expression plasmid for YAP5SA was obtained from Dr. Dawang Zhou and Dr. Lanfen Zhen [25]. The sense sequences of the YAP small interfering RNAs (siRNAs) (siYAPs, Sigma, Shanghai, China) were as follows:

YAP siRNA#1: 5′-GCAAGCUUCCUGGCAGAGATT-3′,
YAP siRNA#2: 5′-GGUGAUACUAUCAACAAAATT-3′.

**Immunohistochemistry and western blotting**

We performed immunohistochemical staining and western blotting using methods that have been described previously [24]. Anti-YAP (1:100, immunohistochemistry), Anti–phosphorylated-YAP (p-YAP) (Ser127) (1:1000, western blot), and anti–p-LATS1 (Ser909) (1:1000, western blot) were from Cell Signaling Technology (Shanghai, China). Anti-YAP (1:1000, western blot), anti-LDH (1:1000, western blot), anti-PKM2 (1:1000, western blot), anti-Glut1 (1:1000, western blotting), and anti–HIF-1α (1:1000, western blot) rabbit monoclonal antibodies were from Proteintech (Wuhan, China). Anti–matrix metalloproteinase 2 (MMP2, 1:1000, western blot), anti-MMP9
After 24-h culture under hypoxia (1% O₂), the HCC cells were analyzed using Image J software (National Institutes of Health, Bethesda, MD, USA).

Immunofluorescence
The HCC cells were cultured, plated in 6-well plates, washed with phosphate-buffered saline (PBS), and fixed in 4% polyformaldehyde. Primary antibody against YAP (1:100) or HIF-1α (1:100) was added on the plates of cells or frozen sections of HCC tissues, and the plates were incubated at 4 °C overnight. After washing, we added fluorescein isothiocyanate (FITC)-labeled (1:100) secondary antibody (Beyotime, Shanghai, China) and incubated the samples for 2 h. We counterstained the cells using diamidophenylindole (DAPI, Beyotime, Shanghai, China) and visualized them under a confocal microscope.

In vitro migration and invasion
We assessed HCC cell migration and invasive capability using 24-well Transwell plates with or without Matrigel (BD), respectively. Then cells (1 × 10⁵) in serum-free culture medium were plated in the top chamber. High-glucose Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS was added to the bottom chamber. After 24-h incubation, the membrane was washed with PBS, fixed using 4% paraformaldehyde, and stained using 0.1% crystal violet solution. The cells were counted in five random fields under microscopy. We performed the experiment in triplicate and repeated it three times.

Extracellular acidification rate (ECAR)
The Seahorse XFe 96 Extracellular Flux Analyzer (Seahorse Bioscience) was used to determine the extracellular acidification rate (ECAR). ECAR was examined with a Seahorse XF glycolysis stress test kit according to the manufacturer’s protocols. In brief, cells (1 × 10⁶ cells / well) were seeded into a Seahorse XFe 96 cell culture plate. After baseline measurements, glucose, oligomycin, and 2-DOG were sequentially injected into each well at the time points specified. ECAR data were assessed by Seahorse XF-96 Wave software and shown in mpH/ minute.

Lactate and glucose level measurement
Lactate Assay Kit II (Sigma, Shanghai, China) and High Sensitivity Glucose Assay Kit (Sigma, Shanghai, China) were used according to the manufacturer’s instructions to detect HCC cell lactate and glucose levels, respectively.

Co-immunoprecipitation
After 24-h culture under hypoxia (1% O₂), the HCC cells were collected and incubated with 300 μl lysis buffer with protease inhibitors for 40 min on ice. Then, the supernatant was collected, and 2 μg HIF-1α, YAP, or immunoglobulin G (IgG) (Proteintech) antibody was added and incubated at 4 °C overnight. Next, 20 μl protein A/G-agarose beads (Santa Cruz Biotechnology, Shanghai, China) was added and rocked for 3 h at 4 °C. The pelleted cells were collected and washed three times with lysis buffer. Finally, the precipitate was boiled with 40 μl loading buffer for 5 min and analyzed by western blotting.

Subcellular fractionation
HCC tissues or HCC cells cytoplasmic and nuclear extracts were separated using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, Shanghai, China) according to the manufacturer instructions. Then, YAP expression was analyzed by western blotting.

Cycloheximide (CHX) chase assay
CHX chase assay was used to determine the half-life of HIF-1α. YAP knockdown or control HCC cells were individually seeded in 60-mm dishes for 24 h. Then, the cells were cultured under hypoxia (1% O₂) for 24 h and treated with CHX (100 μg/ml) for 0 h, 2 h, and 4 h. The cells were collected at the indicated time points, and HIF-1α expression was analyzed by western blotting.

Chromatin immunoprecipitation (ChIP) assay
Cells or cells transfected with YAP siRNA were cultured under hypoxic condition (1%O₂) for 24 h. Then ChIP assay was performed using the EZ-ChIP kit (17–371, Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. The immunoprecipitated DNA was purified and analyzed by real-time PCR. Primer information used in ChIP assays was listed as follows:

**PKM2:** Forward: 5’-TTCCCTGCCTCTTGGATGAC-3’, Reverse: 5’-CGGCTTGTCCCTCCTAC-3’

Luciferase reporter assay
The PKM2 promoter reporter plasmids were amplified from a human genomic DNA template and inserted into pGL3-Promoter Vector (Promega, Madison, WI). Cell were seeded in a 96-well plate and co-transfected with PKM2 promoter reporter plasmids (wt) or mutation of PKM2 promoter reporter plasmids and the 8xGTTIC-luciferase plasmid using Invitrogen Lipofectamine 3000 (Thermo Fisher Scientific, Shanghai, China) as per instructions from the manufacturer. Then cells were cultured under hypoxic condition (1%O₂) or normoxic condition (20%O₂) for 24 h. Luciferase activities were analyzed using the Dual-luciferase reporter assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions.
Gene set enrichment analysis (GSEA)
The HCC tissues data from TCGA databases were
grouped into two groups based on the expression of
HIF-1α: HIF-1α high expression and HIF-1α low expres-
sion. The gene expression values of the two groups sam-
ple sets were then put through GSEA v3.0 to analyze Hippo
signaling genes signatures. Hippo signaling gene sets
were obtained from the MSigDB database v6.1 [26].

Statistical analysis
We analyzed the data with SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism 6 (GraphPad
Software, San Diego, California, USA). The data are re-
ported as the mean ± SD; Student’s t-test or analysis of
variance was used for the statistical analyses. The correl-
ation between YAP mRNA and HIF-1α mRNA was ana-
lyzed by Pearson’s correlation coefficient using GEPIA.
p-values < 0.05 indicates statistical significance. We re-
peated the experiments three times at minimum.

Results
YAP expression was high in HCC tissues
We firstly investigated YAP expression in 54 cases of
HCC tissues and their paired adjacent nontumor tissues
by real-time PCR and immunohistochemistry. The results
obtained from real-time PCR showed significantly in-
creased YAP mRNA levels in the tumor tissues as com-
pared with the adjacent noncancerous tissues (p = 0.006,
Fig. 1a); Immunohistochemical staining revealed 53.7%
(29/54) HCC tissues were positive for YAP expression,
whereas only 18.5% (10/54) adjacent normal tissues were
positive for YAP expression (Fig. 1b). Then immunofluo-
rescence staining and cell fractionation assays were used to
investigate YAP localization, among the 29 cases of HCC
tissues overexpression YAP, 68.9% (20/29) HCC tissues
showed stronger nuclear YAP staining as opposed to cyto-
plasmic staining (Fig. 1c and d). In addition, we also
analyzed the mRNA levels of two canonical YAP tran-
scription target genes (CTGF, CYR61) in the same HCCs
displaying higher YAP mRNA levels. The results revealed
that expression of CTGF mRNA and CYR61 mRNA
were all increased in the HCC, along with the
up-regulation of YAP mRNA (Additional file 2: Figure S1A).
These results suggest that, in HCC tissues,
YAP expression is high and that YAP is localized to the
nucleus.

YAP correlated strongly with HIF-1α
As a solid tumor, the abnormal new vasculature of the
tumor and the increased consumption of oxygen in the
cell proliferation in HCC are imbalanced, so the inner of
HCC tissues is always hypoxic. Hypoxia promotes HCC
invasion and migration, and hypoxia inducible factor-1α
(HIF-1α) is also up-regulated in HCC. So in order to
evaluate whether HIF-1α correlated with YAP, we firstly
performed gene set enrichment analysis and found
enriched expression of Hippo signaling genes in HCC tissues from The Cancer Genome Atlas (TCGA) database (Fig. 2a). Since YAP is a transcriptional activator in the Hippo signaling, and can also be inhibited by Hippo signaling [8], we then retrieved data on 369 HCC cases from The Cancer Genome Atlas (TCGA) to analyze the relationship between YAP mRNA and HIF-1α mRNA expression, and found a positive correlation between the two \((R = 0.5, P = 1.7E-24)\) (Fig. 2b). Furthermore, we analyzed the relationship between the expression of YAP mRNA and HIF-1α mRNA in 54 cases of HCC tissues. It showed that YAP mRNA expression correlated positively with that of HIF-1α mRNA \((R = 0.64, p < 0.01)\) (Fig. 2c). And western blotting yielded similar results both in the HCC tissues (Fig. 2d) and in the nuclear fraction of HCC (Additional file 2: Figure S1B). Our results suggest that YAP overexpression correlated strongly with HIF-1α in HCC tissues under hypoxia.

Hypoxia activated YAP and induced YAP nuclear translocation in HCC cells

To determine whether hypoxia activates YAP, we incubated HCC cells under hypoxic and normoxic conditions for 24 h. The expression of p-YAP (Ser127) was significantly decreased under hypoxic conditions, while total YAP was not increased, and the protein levels of LATS1 and p-LATS1 (Ser909), the upstream regulators of YAP in the Hippo pathway, were decreased (Fig. 3a and b). It implied that Hippo signaling might be inhibited by hypoxia. As YAP nuclear localization is the key regulatory mechanism for activating YAP, we performed immunofluorescence staining to examine the cellular localization of YAP. Hypoxia triggered significant YAP nuclear translocation in the HCC cells (Fig. 3c and d). Consistent with that, cell fractionation showed more YAP protein accumulation in the nuclear fraction and less YAP protein in the cytoplasmic fraction of hypoxic cells (Fig. 3e and f). In addition, hypoxia also increased the mRNA expression of four canonical YAP transcription target genes (CTGF, CYR61, AREG and EDN1) (Fig. 3g and h). The results suggest that hypoxia activates YAP and induces YAP translocation to the nucleus by inhibiting the Hippo pathway in HCC cells.

Hypoxia promoted HCC cell glycolysis in vitro

Recent studies have reported that hypoxia promotes cancer cell glycolysis [8, 9]. To confirm this, the glucose and lactate assays were performed and the results showed that hypoxia significantly increased HCC cell glucose uptake and lactate production rates, respectively,
compared with normoxia (Fig. 4a and b). Hypoxia also showed increased extracellular acidification rate (ECAR), which reflects overall glycolytic flux (Fig. 4c and d). Usually, hypoxia promotes cancer cell glycolysis by up-regulating the expression of key glycolysis enzymes [27, 28]. So we then performed real-time PCR to detect the expression of key glycolysis enzymes in HepG2 and Huh7 cells under 24 h normoxia or hypoxia. LDHA mRNA, GLUT1 mRNA, PGK1 mRNA, and PKM2 mRNA expression levels were up-regulated in the hypoxic cells than in the normoxic cells, and PKM2 mRNA had a significantly increased among the key glycolysis enzymes (Fig. 4e), western blotting yielded similar results (Fig. 4f). Besides that, as a potent micro-environmental factor, hypoxia also promotes tumor migration via up-regulation of the expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9) [29–32]. We then examined HCC cell invasion and migration under normoxia and hypoxia using Transwell assays. Hypoxia significantly promoted HCC cell migration and invasion when compared with normoxia (Fig. 4g and h). Moreover, the hypoxic cells had higher MMP2 and MMP9 expression than the normoxic cells (Fig. 4i and j). These results suggest that hypoxia contributes to HCC cell glycolysis, invasion, and migration.

**Silencing YAP inhibited HCC cell glycolysis under hypoxia**

To investigate the role of YAP in hypoxic HCC cells, we knocked down YAP expression in HCC cells using YAP siRNA. The knockdown efficiency was examined using real-time PCR and western blotting (Fig. 5a and b). Silencing YAP under hypoxia significantly decreased the HCC cell glucose uptake and lactate production rates compared with control cells (Fig. 5c and d). In addition, silencing YAP also decreased extracellular acidification rate (ECAR) (Fig. 5e and f) in HCC cells under hypoxic condition. These results indicated that YAP knockdown might inhibit HCC cell glycolysis under hypoxia. To further confirm the hypothesis, we examined the expression of PKM2 and activated YAP in YAP knockdown cells under hypoxia. It showed that YAP knockdown also decreased the expression of PKM2 and HIF-1α protein (Fig. 5g and h). However, it did not significant change the level of HIF-1α mRNA, although it decreased the PKM2 mRNA level (Additional file 3: Figure S2A and B). Moreover, activating YAP restored the expression of...
HIF-1α protein and PKM2 mRNA (Additional file 3: Figure S2C and E) and HCC cell glycolysis under hypoxia (Additional file 3: Figure S2F and G). Furthermore, silencing YAP significantly inhibited the invasion and migration of hypoxic HCC cells (Fig. 5i and j) and decreased MMP2 and MMP9 protein expression in hypoxic cells (Fig. 5k and l). Our findings indicate that YAP can mediate hypoxia-induced glycolysis in HCC cells.

**YAP bound and sustained HIF-1α stability to promote glycolysis in HCC cells under hypoxia**

To investigate the molecular mechanism of YAP in contributing to hypoxia-induced glycolysis in HCC cells, the cellular localization of YAP and HIF-1α was examined using immunofluorescence staining. Hypoxia greatly promoted YAP and HIF-1α accumulation in the nucleus (Fig. 6a and b). As hypoxia triggered both YAP and HIF-1α nuclear translocation, we believe that YAP may complex with HIF-1α in the nucleus under hypoxia. Co-immunoprecipitation confirmed that YAP could bind HIF-1α under hypoxic conditions (Fig. 6c). However, silencing YAP significantly decreased HIF-1α protein expression under hypoxia and did not change the level of HIF-1α mRNA, so we wondered whether YAP could sustain HIF-1α stabilization. We used CHX chase assays to explore the effect of YAP on HIF-1α stability, and found...
that YAP knockdown cells had significantly shortened HIF-1α half-life compared with the control cells (Fig. 6d). The results indicated that YAP bound HIF-1α to form a complex and sustained HIF-1α stability. As shown in Figs. 4 and 5, we found the expression of PKM2 was significantly changed, so we further wondered whether YAP/HIF-1α complexes could bind target PKM2 gene to promote HCC cells glycolysis in hypoxia. Since YAP has no DNA-binding domains, and binds to its target genes promoters by interacting with DNA-binding transcription factors [33, 34], so we focused on HIF-1α and analyzed HIF-1α and PKM2 gene sequence. Finally, we found a candidate HRE (HIF-1α binding site 5’-ACGTG-3’) in PKM2 promoter. To determine whether YAP/HIF-1α complexes bind at this site, chromatin immunoprecipitation (ChIP) assay was performed in HCC cells under hypoxia. The results showed that ChIP with HIF-1α or YAP antibody enriched the putative HRE sequence > 5 fold compared to
IP with IgG (Fig. 6e). In contrast, after silencing YAP, the enrichment of PKM2 with HIF-1α or YAP antibody was significantly decreased compared with IgG (Fig. 6f). These data indicated that YAP/HIF-1α complexes could bind to the promoter of PKM2 gene. In addition, we also used luciferase reporter assay to test whether this putative HRE in the PKM2 gene is functional. As shown in Fig. 6g, this putative HRE in the PKM2 gene significantly increased luciferase activity in hypoxic HCC cells, however, mutation HRE significantly decreased hypoxia-induced luciferase activity. Taken together, these data indicated that YAP/HIF-1α complexes bound to PKM2 gene promoter and directly activated its transcription to accelerate glycolysis in hypoxia.

**Discussion**

YAP is a powerful regulator and is overexpressed in many cancers, including HCC [35, 36]. It plays important roles in cell proliferation, glycolysis, and survival [37, 38]. In our study, we found that YAP was up-regulated in HCC tissues compared to the adjacent normal tissues, and high YAP expression always accumulated in HCC.
cell nuclei. Analysis of TCGA public data sets using GSEA and GEPIA revealed that YAP correlated positively with HIF-1α levels in HCC tissues, and the results was further confirmed in our 54 cases of HCC tissues. In addition, YAP knockdown significantly decreased PKM2 expression and inhibited glucose uptake and lactate production rates in hypoxic HCC cells. As hypoxia regulates cell glycolysis via HIF-1α [39–41], we speculated that YAP might be involved in promoting HCC cell glycolysis via hypoxia.

YAP has been identified as a downstream effector of multiple inputs, such as the Hippo [42], WNT/β-catenin [43], and Janus kinase (JNK) [44] pathways. Recently, novel mechanisms between hypoxia and YAP have garnered increased attention. Ma et al. reported that SIAH2 (Siah 2E3 ubiquitin ligase 2), an essential hypoxia pathway component, inhibits the Hippo pathway and activates YAP by destabilizing LATS2 under hypoxia [45]. Zhou et al. found that hypoxia promoted cell survival and inhibited apoptosis by inducing YAP nuclear translocation, and YAP activation led to Sorafenib resistance in HCC cells [46]. In the present study, hypoxia promoted HCC cell glycolysis by decreasing p-YAP expression and triggering YAP nuclear translocation. The decreased p-YAP expression under hypoxia is consistent with the results of Yan et al. [47]. Furthermore, YAP knockdown significantly decreased PKM2 expression and inhibited glucose uptake and lactate production rates in hypoxic HCC cells. These results indicate that YAP is essential for hypoxia-triggered glycolysis in HCC cells. Subsequently, we studied the potential molecular mechanism involved.

Ma et al. showed that, under hypoxia, HIF-2α up-regulation of YAP occurred via neither kinase signaling nor protein–protein interaction [48]. Dai et al. also showed that HIF-1α did not mediate hypoxia-triggered YAP nuclear translocation [17]. However, in the present study, LATS1 and p-LATS1 (Ser909) expression levels were decreased under hypoxia. LATS1 is the core protein in the Hippo pathway and is also the upstream regulator of YAP. Upon Hippo pathway activation, p-LATS1 phosphorylates YAP, which is subsequently confined to the cytoplasm or is degraded [49]. Our data show that hypoxia decreased LATS1 and p-LATS1 (Ser909) expression to inhibit the Hippo pathway and activate YAP. Moreover, hypoxia triggered both YAP and HIF-1α nuclear translocation; co-immunoprecipitation confirmed that hypoxia enhanced YAP and HIF-1α interaction. As silencing YAP decreased HIF-1α protein expression, it is possible that YAP is important for HIF-1α stability under hypoxia. To demonstrate this, the CHX chase assays showed significantly shortened half-life of HIF-1α in the YAP knockdown cells compared with the control cells. YAP is a transcriptional co-activator and has no DNA-binding domains [50]. So YAP does not directly bind to the promoter of downstream target genes to activate them, such as PKM2. YAP is mainly dependent on multiple domains to interact with transcription factors and form a complex to promote the expression and activation of downstream target genes in nucleus [51]. Therefore, we revealed that YAP/HIF-1α complexes binds at 5′-ACGTG-3′ in PKM2 gene promoter and directly activates its transcription. Taken together, our findings indicate that YAP forms a complex with HIF-1α in the nucleus and sustains HIF-1α stability to bind to PKM2 gene and directly activates its transcription to accelerate glycolysis in HCC cells under hypoxia.

Conclusions
In summary, our study demonstrated that YAP expression was high in HCC tissues and correlated positively with the expression of HIF-1α and PKM2. Hypoxia promotes HCC cell glycolysis via YAP activation by decreasing p-YAP expression and triggering YAP nuclear translocation. YAP activation interacts directly with HIF-1α in the nucleus and sustains HIF-1α stability to activate PKM2 transcription. The HIF-1α–YAP regulatory axis may provide a better understanding of the molecular mechanism of HCC glycolysis and progression, and YAP may be a potential therapeutic target in HCC.

Additional files

Additional file 1: Real-time PCR primers. (DOC 32 kb)

Additional file 2: Figure S1. YAP expression was high in HCC tissues. (a) Real-time PCR was used to examine the expression of CTGF mRNA and CYR61 mRNA in the 29 case HCC displaying higher YAP mRNA levels, (b) Western blot showed the representative expression of YAP and HIF-1α in the nuclear fraction of HCC tissues and adjacent tissues. Data are shown as the mean ± SEM of three independent experiments. (TIF 1037 kb)

Additional file 3: Figure S2. Silencing YAP inhibited HCC cell glycolysis under hypoxia. (a–b) Real-time PCR was used to examine the expression of HIF-1α mRNA and PKM2 mRNA in HepG2 and Huh7 cells under hypoxia (1%O2) for 24 h after transfected with YAP siRNA. (c) Western blot was used to examine the expression of HIF-1α and PKM2 protein in HepG2 and Huh7 cells under hypoxia (1%O2) for 24 h after transfected with YAP siRNA or YAPSSA. (d–e) Real-time PCR was used to examine the expression of HIF-1α mRNA and PKM2 mRNA in HepG2 and Huh7 cells under hypoxia (1%O2) for 24 h after transfected with YAP siRNA or YAPSSA. Data shown as the mean ± SEM of three independent experiments. #p > 0.05; *p < 0.05. (TIF 1269 kb)

Abbreviations
CHX: Cycloheximide; Glut1: Glucose transporter 1; HCC: Hepatocellular carcinoma; HIF-1α: Hypoxia-inducible factor-1α; LATS1: Large tumor suppressor kinase 1; LDHA: Lactate dehydrogenase A; MMP2: Matrix metallopeptidase 2; MMP9: Matrix metallopeptidase 9; PGK1: Phosphoglycerate kinase 1; PKM2: Pyruvate kinase M2; YAP: Yes-Associated Protein

Acknowledgements
We are particularly grateful to Dr. Dawang Zhou and Dr. Lanfen Zheng for providing the plasmid of YAPSSA.
8. Cui XG, Han ZT, He SH, Wu XD, Chen TR, Shao CH, et al. HIF1/2alpha mediates the expression of LDHA in human hepatocellular carcinoma cells. Oncotarget. 2017;8:24840–52. https://doi.org/10.18632/oncotarget.15266.

9. Zhang LF, Lou JT, Lu MH, Gao C, Zhao S, Li B, et al. Suppression of miR-199a maturation by HIF is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J. 2015;34:2671–85. https://doi.org/10.1525/embj.201591803.

10. Wan W, Peng X, Li M, Qin L, Tong Z, Yan J, et al. Histone demethylase JMJD1A induces urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor-1alpha. Oncogene. 2017;36:3868–77. https://doi.org/10.1038/onc.2017.13.

11. Zhang Y, Ren YJ, Guo LC, J G, Hu J, Zhang HH, et al. Nuclear accumbents-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1alpha axis. Oncogene. 2017;36:471–81. https://doi.org/10.1038/onc.2017.51.

12. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Connerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–33. https://doi.org/10.1016/j.cell.2007.07.019.

13. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–85. https://doi.org/10.1002/ijc.24180.

14. Perra A, Kowalk MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088–96. https://doi.org/10.1016/j.jhep.2014.06.033.

15. Yilmalam D, Fowl BH, Camardo FD. Emerging evidence on the role of the hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63:1491–501. https://doi.org/10.1016/j.jhep.2015.07.008.

16. Li C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1-HER3-Induced signalling axis modulates the hippo-YAP pathway to regulate bone migration. Nat Cell Biol. 2017;19:106–19. https://doi.org/10.1038/ncb3464.

17. Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH, et al. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7:9693–47. https://doi.org/10.18632/oncotarget.6903.

18. Wang Z, Liu P, Zhou X, Wang T, Feng X, Sun YP, et al. Endothelin promotes colorectal tumorigenesis by activating YAP/TAZ. Cancer Res. 2017;77:2413–23. https://doi.org/10.1158/0008-5472.CAN-16-3229.

19. Wang W, Xiao ZD, Li X, Azz GE, Gan B, Johnson RL, Chen J. AMPK modulates hippo pathway activity to regulate energy homeostasis. Nat Cell Biol. 2015;17:490–9. https://doi.org/10.1038/ncb3113.

20. DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like-1 protein. Cell Rep. 2014;9:495–503. https://doi.org/10.1016/j.celrep.2014.09.036.

21. Enzo E, Santinon G, Pocratara A, Aragona M, Bresolin S, Forcati M, et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 2015;34:13469–80. https://doi.org/10.1525/embj.201440379.

22. Hu Y, Shin DJ, Pan H, Lin Z, Dreyfuss JM, Camargo FD, et al. YAP induces gluconeogenic gene expression through PGC1alpha. Hepatology. 2017;66:2029–41. https://doi.org/10.1002/hep.29375.

23. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEP1A: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102. https://doi.org/10.1093/nar/gkw247.

24. Zhang X, Fan Q, Li Y, Yang Z, Yang L, Zong Z, et al. Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of hippo signaling. Oncotarget. 2017;8:29785–94. https://doi.org/10.18632/oncotarget.14523.

25. Shen S, Guo X, Yan H, Zhou D, Zhang L, Zhao B, et al. miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 2015;25:907–102. https://doi.org/10.1038/cr.2015.98.

26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. https://doi.org/10.1073/pnas.0506580102.

27. Wang H, Zhao L, Zhu LT, Wang Y, Pan D, Yao J, et al. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-alpha and glycolysis by inhibiting PI3K/Akt signaling pathway. Mol Carcinog. 2014;53:E107–18. https://doi.org/10.1002/mc.22052.

28. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012;109:E3367–76. https://doi.org/10.1073/pnas.1217394109.
29. Pouyssegur J, Dayan F, Mazure NK. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43. https://doi.org/10.1038/nature04871.

30. Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3. https://doi.org/10.1186/1756-8722-6-3.

31. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, et al. MYC-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells. Oncotarget. 2017;8:48983–90. https://doi.org/10.18632/oncotarget.16904.

32. Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is a prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110. https://doi.org/10.1186/1476-4598-13-110.

33. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF homeostasis, and Cancer. Cell. 2015;163:811–828. https://doi.org/10.1016/j.cell.2015.10.044.

34. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of YAP and TAZ in common solid tumors. Hum Pathol. 2008;39:1582–9. https://doi.org/10.1016/j.humpath.2008.04.012.

35. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and Cancer. Cell. 2015;163:811–28. https://doi.org/10.1016/j.cell.2015.10.044.

36. Moroishi T, Hansen CG, Guan KL. YAP and TAZ: a nexus for hippo signaling and beyond. Trends Cell Biol. 2015;25:499–513. https://doi.org/10.1016/j.tcb.2015.05.002.

37. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. Genome-wide association between YAP/TAZ, TEAD and AP-1 enhancers drives oncogenic growth. Nat Cell Biol. 2015;17:1218–27. https://doi.org/10.1038/ncb3216.